Source-grounded facts extracted from PANACEA LIFE SCIENCES HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Agreement with Sky Wellness, LLC (effective 2024-05-13).
“On May 13, 2024, Panacea Life Sciences, Inc., a subsidiary of Panacea Life Sciences Holdings, Inc. (the “Company,” “Panacea Life Sciences,” “we,” or “our”) entered into a definitive Licensing, Marketing, Supply and Development Agreement (the “Agreement”) with Sky Wellness, LLC, an Arizona limited liability company (“Sky Wellness”)”
PANACEA LIFE SCIENCES HOLDINGS, INC. dismissed BF Borgers CPA PC as its auditor.
“On May 6, 2024, Panacea Life Sciences Holdings, Inc. (the “Company”) dismissed BF Borgers CPA PC (“BF Borgers”) as the Company’s independent registered public accounting firm.”
PANACEA LIFE SCIENCES HOLDINGS, INC. incurred convertible notes of $385,000 Senior Convertible Note with an institutional investor maturing March 3, 2022 (dated); repayment terms include a Note Payoff Agreement dated February 9, 2023.
“the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”). The parties have agreed that the Company will repay the Note in full pursuant to the terms of a Note Payoff Agreement dated February 9, 2023”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (effective 2022-03-03).
“On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Asset Purchase Agreement with PLM Holdings, Inc. valued at $180,000 promissory note (effective 2024-01-29).
“On January 29, 2024, Panacea Life Sciences Holdings, Inc., a Nevada corporation (“Panacea” or the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with PLM Holdings, Inc., a Colorado corporation (“PLM Holdings”), whereby PLM Holdings acquired from the Company all assets owned by the Company of and relating to the PUR Life Medical System and assumed certain liabilities from the Company relating to the PUR Life Medical System. In compensation to the Company under the Purchase Agreement, PLM Holdings issued to the Company a promissory note for the aggregate purchase price of $180,000.”
PANACEA LIFE SCIENCES HOLDINGS, INC.: Filed Certificate of Designation establishing Series N-7 Preferred Stock with specified rights and preferences (effective 2023-10-05).
“On October 5, 2023, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada (the “Certificate of Designation”), which established 78,530 shares of the Series N-7 Preferred Stock, par value $0.001 per share, having such designations, rights and preferences as set forth in the Certificate of Designation, as determined by the Company’s Board of Directors in its sole discretion, in accordance with the Company’s Certificate of Incorporation and Bylaws.”
PANACEA LIFE SCIENCES HOLDINGS, INC. completed an acquisition involving Lizard Juice, LLC, Gary Wilder, New Age Distribution, LLC, and N7 Enterprises, Inc. for 78,530 shares of a newly authorized class of convertible preferred stock of the Company (the "Series N-7 Preferred") (closed 2023-09-30).
“on September 30, 2023, the Company completed its acquisition of certain assets related to the Nitro Kava Business from the Sellers in exchange for the issuance of 78,530 shares of N-7 Preferred.”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Asset Purchase Agreement with Lizard Juice, LLC, Gary Wilder, New Age Distribution, LLC, and N7 Enterprises, Inc. valued at 78,530 shares of a newly authorized class of convertible preferred stock of the Company (the "Series (effective 2023-09-30).
“On September 30, 2023, Panacea Life Sciences Holdings, Inc., a Nevada corporation ("Panacea" or the "Company") consummated the transactions contemplated by the Asset Purchase Agreement dated as of June 30, 2023 among Lizard Juice, LLC, a Delaware limited liability company ("Lizard Juice"), Gary Wilder, ("Wilder"), New Age Distribution, LLC, a Florida limited liability company ("New Age Distribution"), and N7 Enterprises, Inc., a Florida corporation and the parent company of Lizard Juice and New Age Distribution ("N7 Enterprises" and together with Lizard Juice, Wilder and New Age Distribution, the "Sellers") and the Company”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Asset Purchase Agreement with PUR Life Medical, Inc. valued at $180,000 (effective 2023-09-26).
“On September 26, 2023, Panacea Life Sciences Holdings, Inc. (the “Company,” “Panacea,” “we,” or “our”) and PUR Life Medical, Inc. (“PUR Life”) entered into an Asset Purchase Agreement (“APA”) pursuant to which PUR Life agreed to sell and Panacea agreed to purchase all of the following assets”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Asset Purchase Agreement with Lizard Juice, LLC, Gary Wilder, New Age Distribution, LLC, and N7 Enterprises, Inc. valued at 84,548 shares of Series E Preferred stock (effective 2023-07-03).
“On July 3, 2023 Panacea Life Sciences Holdings, Inc. (“Panacea” or the “Company”) entered into an asset purchase agreement (the “APA”) with Lizard Juice, LLC, a Delaware limited liability company (“Lizard Juice”), Gary Wilder, an individual resident of Florida (“Wilder”), New Age Distribution, LLC, a Florida limited liability company (“New Age Distribution”), and N7 Enterprises, Inc., a Florida corporation and the parent company of Lizard Juice and New Age Distribution (“N7 Enterprises” and together with Lizard Juice, Wilder and New Age Distribution, the “Seller”), pursuant to which, subject to the satisfaction of certain closing conditions, the Company will acquire certain of the assets of Seller for 84,548 shares of a newly authorized class of convertible preferred stock of the Company (the “Series E Preferred”), including eight Kava Nitro stores in the Tampa, Florida area, including inventory, equipment and recipes, distribution facilities and a warehouse.”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Exchange of 350 shares of Series A Preferred Stock for Senior Convertible Note of $385,000, subseque (effective 2022-03-03).
“On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).”
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Securities Purchase Agreement with an institutional investor valued at $1,000,000 (effective 2021-11-16).
“On November 16, 2021, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) pursuant to which the Company sold a 10% original issue discount senior convertible promissory note in the principal amount of $1,100,000 (the “Note”) and five-year warrants to purchase 785,715 shares of the Company’s common stock, par value $0.0001 per share at an exercise price of $1.40 per share (the “Warrants”) pursuant to the terms and conditions of the SPA for a total purchase price of $1,000,000.”
Janice Nerger resigned as Director at PANACEA LIFE SCIENCES HOLDINGS, INC..
“On July 21, 2022, Dr. Janice Nerger resigned as a member of the Board of Directors of Panacea Life Sciences Holdings, Inc., effective immediately.”
Dr. Janice Nerger was appointed as director at PANACEA LIFE SCIENCES HOLDINGS, INC..
“On October 17, 2021, following Exactus, Inc. (the “Company”) compliance with Rule 14f-1 under the Securities Exchange Act of 1934, Dr. Janice Nerger officially became a director of the Company.”
Mr. Wert resigned as Executive Chairman at PANACEA LIFE SCIENCES HOLDINGS, INC..
“Mr. Wert previously was Executive Chairman but resigned from that role.”
John Price resigned as director at PANACEA LIFE SCIENCES HOLDINGS, INC..
“John Price, a director (who had not held any officer positions with the Company), previously resigned from as a director of the Company.”
Leslie Buttorff was appointed as director at PANACEA LIFE SCIENCES HOLDINGS, INC..
“Leslie Buttorff was appointed director.”
Julian Pittam resigned as director at PANACEA LIFE SCIENCES HOLDINGS, INC..
“On June 30, 2021, Julian Pittam resigned as director of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.